Patents by Inventor Neil Bodick

Neil Bodick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180311260
    Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.
    Type: Application
    Filed: March 27, 2018
    Publication date: November 1, 2018
    Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
  • Patent number: 9949987
    Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: April 24, 2018
    Assignee: Flexion Therapeutics, Inc.
    Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
  • Publication number: 20170258815
    Abstract: This invention relates to the use of corticosteroids in patients with diabetes, including patients with type 2 diabetes, to treat pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis without increasing or otherwise significantly impacting blood glucose concentrations in diabetic patients, and to slow, arrest or reverse structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or periarticular tissues caused by osteoarthritis or rheumatoid arthritis without increasing or otherwise impacting blood glucose concentrations. More specifically, a formulation of triamcinolone acetonide (TCA) is administered locally to diabetes patients, including type 2 diabetes patients, as a sustained release dosage form (with or without an immediate release component) that results in efficacy levels accompanied by clinically insignificant or no measurable effect on blood glucose levels.
    Type: Application
    Filed: March 14, 2017
    Publication date: September 14, 2017
    Inventor: Neil Bodick
  • Publication number: 20170182068
    Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.
    Type: Application
    Filed: March 15, 2017
    Publication date: June 29, 2017
    Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
  • Publication number: 20170135957
    Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.
    Type: Application
    Filed: January 31, 2017
    Publication date: May 18, 2017
    Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
  • Publication number: 20170100411
    Abstract: This invention relates to compositions and methods for achieving and maintaining maximal analgesic effect following intra-articular administration of corticosteroid formulations. The invention also describes extended release, e.g., controlled- or sustained-release corticosteroid formulations, including extended release, e.g., controlled- or sustained-release formulations of triamcinolone acetonide (TCA), fluticasone propionate, cortisol, ciclesonide (monopropionate), beclometasone diproprionate, dexamethasone, flunisolide, budesonide, desisobutyryl-ciclesonide, and/or mometasone furoate, that produce a maximal analgesic effect greater than the acute analgesic effect provided by standard corticosteroid suspensions, including non-extended release corticosteroid suspensions, and that are also associated with a clinically insignificant effect on endogenous cortisol production following administration, for example, intra-articular, intrathecal, epidural, intra-bursal, or other local administration.
    Type: Application
    Filed: October 13, 2016
    Publication date: April 13, 2017
    Inventors: Neil Bodick, Derek Jackson, Toni Williamson
  • Patent number: 9555047
    Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: January 31, 2017
    Assignee: FLEXION THERAPEUTICS, INC.
    Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
  • Patent number: 9555048
    Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: January 31, 2017
    Assignee: FLEXION THERAPEUTICS, INC.
    Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
  • Publication number: 20150025050
    Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.
    Type: Application
    Filed: August 18, 2014
    Publication date: January 22, 2015
    Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
  • Publication number: 20140356437
    Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.
    Type: Application
    Filed: August 18, 2014
    Publication date: December 4, 2014
    Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
  • Patent number: 8828440
    Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: September 9, 2014
    Assignee: Flexion Therapeutics, Inc.
    Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
  • Publication number: 20140242170
    Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.
    Type: Application
    Filed: December 16, 2013
    Publication date: August 28, 2014
    Applicant: FLEXION THERAPEUTICS, INC.
    Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
  • Publication number: 20120288534
    Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.
    Type: Application
    Filed: March 16, 2012
    Publication date: November 15, 2012
    Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
  • Publication number: 20120282298
    Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.
    Type: Application
    Filed: February 8, 2012
    Publication date: November 8, 2012
    Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
  • Patent number: 4945476
    Abstract: A knowledge base having particular utility as a medical/pathology knowledge base contains textual and pictorial information on various diseases. The knowledge base includes user-selectable designations of diagnostic features which are characteristic of respective conditions to be diagnosed. These features comprise a case record and several case records are stored and retrieved for subsequent display of the features therein and of one or more pictorial images of those features. The pictorial images preferably are stored on a device such as an optical disk; and these pictorial images are linked to case records which may be stored in other storage devices, such as magnetic disk, whereby the retrieval of a case record accesses the linked pictorial images, whereby those pictorial images and features of the case record are displayed.
    Type: Grant
    Filed: February 26, 1988
    Date of Patent: July 31, 1990
    Assignee: Elsevier Science Publishing Company, Inc.
    Inventors: Neil Bodick, Andre L. Marquis